VolitionRX Ltd
VNRX
查看詳細走勢圖
0.262USD
-0.006-2.21%
收盤 12/19, 16:00（美東）報價延遲15分鐘
28.67M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-2.21%
5天
-2.79%
1月
-21.61%
6月
-71.58%
今年開始到現在
-56.42%
1年
-61.31%
查看詳細走勢圖
TradingKey VolitionRX Ltd股票評分
單位: USD 更新時間: 2025-12-19操作建議
VolitionRX Ltd當前公司基本面數據相對謹慎，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名166/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價2.50。中期看，股價處於下降通道。近一個月，市場表現非常差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
VolitionRX Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
6
分析師
買入
評級
2.500
目標均價
+740.34%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
VolitionRX Ltd亮點
亮點風險
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
業績高增長
公司營業收入穩步增長，連續3年增長302.59%
業績增長期
公司處於發展階段，最新年度總收入1.23M美元
估值高估
公司最新PE估值-1.13，處於3年歷史高位
機構加倉
最新機構持股23.92M股，環比增加6.70%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉78.00K股
VolitionRX Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
VolitionRX Ltd簡介
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
公司代碼VNRX
公司VolitionRX Ltd
CEOButera (Salvatore Thomas)
網址https://volition.com/
常見問題
VolitionRX Ltd(VNRX)的當前股價是多少？
VolitionRX Ltd(VNRX)的當前股價是 0.262。
VolitionRX Ltd 的股票代碼是什麼？
VolitionRX Ltd的股票代碼是VNRX。
VolitionRX Ltd股票的52週最高點是多少？
VolitionRX Ltd股票的52週最高點是0.940。
VolitionRX Ltd股票的52週最低點是多少？
VolitionRX Ltd股票的52週最低點是0.234。
VolitionRX Ltd的市值是多少？
VolitionRX Ltd的市值是28.67M。
VolitionRX Ltd的淨利潤是多少？
VolitionRX Ltd的淨利潤為-26.97M。
現在VolitionRX Ltd(VNRX)的股票是買入、持有還是賣出？
根據分析師評級，VolitionRX Ltd(VNRX)的總體評級為買入，目標價格為2.500。
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是多少
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是-0.227。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
